Everolimus

AUG 20, 2026 · PHASE 2 TRIAL

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

ClinicalTrials.gov

Phase 2 interventional trial with planned enrollment of 333 participants comparing PF-07220060 plus fulvestrant to physician's choice in HR+/HER2− advanced breast cancer; registry record reports no results yet.

AUG 20, 2026 · PHASE 3 TRIAL

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; the planned design is rigorous but outcomes remain unknown and unverified.

AUG 20, 2026 · PHASE 2 TRIAL

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

ClinicalTrials.gov

This is a Phase 2 trial still recruiting with no results posted; it represents early-phase investigation of lutetium Lu 177 dotatate versus everolimus in bronchial neuroendocrine tumors.

AUG 17, 2026 · PHASE 1 TRIAL

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer

ClinicalTrials.gov

Phase 1 safety study with completed enrollment of 26 participants examining everolimus dosing in combination with radiotherapy; no results posted in this registry record.

MAY 12, 2026 · REGULATORY APPROVAL

FDA approval: Everolimus

U.S. Food and Drug Administration

FDA approval of a generic everolimus formulation; confirms regulatory clearance but does not report clinical efficacy or comparative trial data.